A Single Arm, Open Label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO4, a CAR T-cell Treatment Targeting TRBC1, in Patients With Relapsed or Refractory TRBC1 Positive Selected T Cell Non-Hodgkin Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 01 Dec 2018
At a glance
- Drugs CAR-T cell therapies (Primary)
- Indications Anaplastic large cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Autolus
- 01 Dec 2018 According to Autolus media release, the first patient has been dosed in this study.
- 19 Jul 2018 Status changed from not yet recruiting to recruiting.
- 07 Jul 2018 Status changed from planning to not yet recruiting.